Despite seeing sales through its US Sagent unit hit by supply issues with CMOs, Nichi-Iko says its US profits have increased on the back of newly-launched products. However, this failed to offset the impact of NHI price revisions in Japan, dragging down profits in the first nine months of the year.

Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.

Regulators in North America and Europe are reacting to the discovery of the impurity NMDA in ranitidine, just over a year after similar impurities in sartan products led to a slew of recalls and withdrawals around the world.